Blarcamesine
id:
blarcamesine-216-1788641
title:
Blarcamesine
text:
Blarcamesine is an experimental drug which is under development for the treatment of Alzheimer's disease and a variety of other indications. Blarcamesine acts as an agonist of the sigma σ1 receptor, the muscarinic acetylcholine M1 receptor, and the ionotropic glutamate NMDA receptor. The drug was developed by Anavex Life Sciences. As of August 2024, it is in preregistration for Alzheimer's disease, phase 2/3 clinical trials for fragile X syndrome and Rett syndrome, phase 2 trials for Parkinson's
brand slug:
wiki
category slug:
encyclopedia
description:
Medication
original url:
https://en.wikipedia.org/wiki/Blarcamesine
date created:
2016-05-25T00:36:01Z
date modified:
2024-09-12T22:36:35Z
main entity:
{"identifier":"Q25110485","url":"https://www.wikidata.org/entity/Q25110485"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/6/68/ANAVEX2-73.svg","width":420,"height":330}
fields total:
13
integrity:
16